Article thumbnail

Enzyme Mechanism and Slow-Onset Inhibition of Plasmodium falciparum Enoyl-Acyl Carrier Protein Reductase by an Inorganic Complex

By Patrícia Soares de Maria de Medeiros, Rodrigo Gay Ducati, Luiz Augusto Basso, Diógenes Santiago Santos and Luiz Hildebrando Pereira da Silva


Malaria continues to be a major cause of children's morbidity and mortality worldwide, causing nearly one million deaths annually. The human malaria parasite, Plasmodium falciparum, synthesizes fatty acids employing the Type II fatty acid biosynthesis system (FAS II), unlike humans that rely on the Type I (FAS I) pathway. The FAS II system elongates acyl fatty acid precursors of the cell membrane in Plasmodium. Enoyl reductase (ENR) enzyme is a member of the FAS II system. Here we present steady-state kinetics, pre-steady-state kinetics, and equilibrium fluorescence spectroscopy data that allowed proposal of P. falciparum ENR (PfENR) enzyme mechanism. Moreover, building on previous results, the present study also evaluates the PfENR inhibition by the pentacyano(isoniazid)ferrateII compound. This inorganic complex represents a new class of lead compounds for the development of antimalarial agents focused on the inhibition of PfENR

Topics: Research Article
Publisher: SAGE-Hindawi Access to Research
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2001). a p o o r ,M .J .D a r ,A .S u r o l i a ,a n dN .S u r o l i a ,“ K i n e t i c determinants of the interaction of enoyl-ACP reductase from Plasmodium falciparum with its substrates and inhibitors,”
  2. (2004). a p o o r ,P .L .S .M u k h i ,N .S u r o l i a ,K .S u g u n a ,a n d A. Surolia, “Kinetic and structural analysis of the increased affinity of enoyl-ACP (acyl-carrier protein) reductase for t r i c l o s a ni nt h ep r e s e n c eo fN
  3. (1913). A.V.Hill,“Thecombinationsofhaemoglobinwithoxygenand with carbon monoxide,” Biochemical Journal,v o l .7 ,n o .5 ,p p .
  4. (2000). Action mechanism of antitubercular isoniazid: activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor,”
  5. (1987). Antimalarial drugs. An update,”
  6. (1999). Apicomplexan plastids as drug targets,”
  7. (2010). B a s s o ,C .Z .S c h n e i d e r
  8. (1997). Cell invasion by the vertebrate stages of Plasmodium,” Trends
  9. (1913). Die Kinetic der
  10. (1995). e y m ,P .M .A l z a r i ,N .H o n o r ´
  11. (1975). Energetics of ligand binding to proteins,”
  12. (1975). Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems,J o h nW i l e y& Sons,
  13. (2001). g u y e n ,A .Q u e m a r d ,H .M a r r a k c h i ,J .B e r n a d o u ,a n dB . Meunier, “The nonenzymaticactivation of isoniazidby
  14. (2005). H a y ,C .A .G u e r r a ,A .J .T a t e m ,P .M .A t k i n s o n ,a n d
  15. (2009). Health Organization, “10 Facts on malaria,” WHO,
  16. (2005). i o l a ,C .F o g g ,F .B a j u n i r w ee ta l . ,“ S u p e r v i s e dv e r s u s unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial,”
  17. (2002). i u ,C .J .R o g e r s ,A .J .F i s h e r ,a n dM .D .T o n e y , “Aminophosphonate inhibitors of dialkylglycine decarboxylase: structural basis for slow binding inhibition,”
  18. (2002). Identification and characterization of tyrosyl radical formation in Mycobacterium tuberculosis catalase-peroxidase
  19. (1994). inhA,ag e n e encoding a target for isoniazid and ethionamide
  20. (1999). Johnsson,“Spontaneous formation of the bioactive formofthetuberculosis drugisoniazid,”Angewandte Chemie,
  21. (1989). Johnston,“Analysis of the kinetic mechanism of the bovine liver mitochondrial dihydroorotate dehydrogenase,”
  22. (1979). Kinetics of Fast Enzyme Reactions: Theory and Practice,
  23. (1998). M c K i e ,K .T .D o u g l a s ,C .C h a ne ta l . ,“ R a t i o n a ld r u g design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria,”
  24. (1994). Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis,”
  25. (2004). Metabolic mapsandfunctions ofthePlasmodium falciparum apicoplast,”
  26. (2004). Mutational analysis of the triclosan-binding region of enoylACP (acyl-carrier protein) reductase from Plasmodium falciparum,”
  27. (2008). New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents,”
  28. (2004). O l i v e i r a ,E .H .S .S o u s a ,L .A .B a s s oe ta l . ,“ A ni n o r g a n i c ironcomplexthatinhibitswild-type andanisoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis,”
  29. (2002). o n g s r i c h a n a l a i ,A .L .P i c k a r d
  30. (1979). orisch, “Steady-state investigations of the mechanism of histidinoldehydrogenase,”
  31. (1996). R o c ka n dJ .E .C r o n a n ,“ Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis,”
  32. (2008). Residence time of receptor —ligand complexes and its effect on biological function,”
  33. (1986). S p e n c e r ,W .W .W a t k i n s ,D .G .S i x s m i t h ,a n dD .K . Koech, “Response of Plasmodium falciparum to dihydrofolate reductase inhibitors
  34. (2008). S u l l i v a n ,J .I .S e k i g u c h ie ta l . ,“ M e c h a n i s ma n d inhibition of saFabI, the enoyl reductase from Staphylococcus aureus,”
  35. (1988). Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues,”
  36. (2003). Single nucleotide polymorphisms in genes associated with isoniazid resistance
  37. (2006). Slow-onset inhibition of 2-transenoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by aninorganiccomplex,”
  38. (1998). Steady-state kinetic mechanism, stereospecificity, substrate and inhibitor specificity of Enterobacter cloacae nitroreductase,”
  39. (2002). Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase,”
  40. (1968). Studies on the mechanism of fatty acid synthesis. 18. Preparation and general properties of the enoylacylcarrierproteinreductases fromEscherichia coli,”
  41. (1995). Studies on the mechanisms of action of isoniazid and ethionamide in the chemotherapy of tuberculosis,”
  42. (1973). T s a i ,M .W .B u r g e t t ,a n dL .J .R e e d ,“ α Keto acid dehydrogenase complexes. XX. A kinetic study of the pyruvate dehydrogenase complex from bovine kidney,”
  43. (1934). The determination of enzyme dissociation constants,”
  44. (2003). The isoniazidNAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance,”
  45. (1995). The mechanism of substrate and coenzyme binding to clostridial glutamate dehydrogenase during reductive amination,”European
  46. (2008). The mode of inhibition of Mycobacterium tuberculosis wild-type and isoniazid-resistant 2-trans-enoyl-ACP(CoA) reductase enzymes by an inorganic complex,” Anti-Infective Agents
  47. (1997). The role of Mn(II)-peroxidase activity of mycobacterial catalase- peroxidase in activation of the antibiotic isoniazid,”
  48. The slow-binding and slow, tight-binding inhibition of enzyme-catalysed reactions,”
  49. (2005). TheirInhibition:Drug Development,CRC Enzyme Inhibitors Series,
  50. (2001). Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase
  51. (2006). Type II fatty acid biosynthesis, a new approach in antimalarial natural product discovery,”
  52. (2010). ua n dP .J .T o n g e ,“ M e c h a n i s ma n di n h i b i t i o no ft h eF a b V Enoyl-ACP reductase fromBurkholderia mallei,”
  53. (2003). V i a l ,P .E l d i n
  54. (1988). Walsh,“The behavior andsignificance of slow-binding enzyme inhibitors,” Advances in enzymology and related areas of molecular biology,